Picavet, L.W.; Samat, A.A.K.; Calis, J.; Nijhuis, L.; Scholman, R.; Mokry, M.; Tough, D.F.; Prinjha, R.K.; Vastert, S.J.; van Loosdregt, J.
CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders. Biomedicines 2024, 12, 1344.
https://doi.org/10.3390/biomedicines12061344
AMA Style
Picavet LW, Samat AAK, Calis J, Nijhuis L, Scholman R, Mokry M, Tough DF, Prinjha RK, Vastert SJ, van Loosdregt J.
CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders. Biomedicines. 2024; 12(6):1344.
https://doi.org/10.3390/biomedicines12061344
Chicago/Turabian Style
Picavet, Lucas Wilhelmus, Anoushka A. K. Samat, Jorg Calis, Lotte Nijhuis, Rianne Scholman, Michal Mokry, David F. Tough, Rabinder K. Prinjha, Sebastiaan J. Vastert, and Jorg van Loosdregt.
2024. "CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders" Biomedicines 12, no. 6: 1344.
https://doi.org/10.3390/biomedicines12061344
APA Style
Picavet, L. W., Samat, A. A. K., Calis, J., Nijhuis, L., Scholman, R., Mokry, M., Tough, D. F., Prinjha, R. K., Vastert, S. J., & van Loosdregt, J.
(2024). CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders. Biomedicines, 12(6), 1344.
https://doi.org/10.3390/biomedicines12061344
